MedTrace Logo

Erythropoietin + Iron Therapy for Anemic Patients Undergoing Aortic Valve Replacement

NCT02390102 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 117

Last updated 2018-07-17

No results posted yet for this study

Summary

The objective of the study is to evaluate the efficacy of Erythropoietin (EPO) (+ iron) in reducing the rate of red blood cell transfusion requirements in patients with aortic stenosis undergoing transcatheter aortic valve replacement.

Conditions

Interventions

DRUG

Erythropoietin

Combinaison drug of darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose

DRUG

Placebo

Saline solution 0.9%

Sponsors & Collaborators

  • Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec

    lead OTHER

Principal Investigators

  • Josep Rodes Cabau, MD · Institut Universitaire de Cardiologie et de Pneumologie de Quebec

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2015-06-30
Completion
2016-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02390102 on ClinicalTrials.gov